Magnetic Resonance Imaging (MRI) Market to Reach USD 10.2 Billion by 2036 as AI Reconstruction and Low-Helium Systems Improve Imaging Efficiency | FMI

Future Market Insights projects the global MRI market to grow from $7.0B in 2026 to $10.2B by 2036 (4.2% CAGR), driven by faster imaging workflows, AI-powered reconstruction (fewer repeat scans), and increasing adoption of low-/helium-free MRI systems that reduce siting complexity. The report also highlights rising MRI waiting-time pressure and higher throughput needs at hospitals, with procurement shifting from simple scanner replacement toward advanced, workflow-integrated platforms supported by reliable service networks.

Analysis

This reads less like a secular unit-expansion story and more like a mix-shift story toward higher-margin software, service, and premium configurations. The biggest winner is whoever can monetize the installed base after the scanner sale: GEHC and SMMNY look best positioned if they can convert AI reconstruction, uptime contracts, and coil/service attach into recurring revenue. PHG can participate, but the market will likely keep demanding evidence that MRI is translating into durable margin expansion rather than just preserving share.

The second-order effect is pressure on smaller MRI vendors and low-service distributors: as hospitals buy fewer standalone boxes and more workflow solutions, OEM differentiation shifts from magnet specs to install friction, uptime, and integration. That favors large players with field service density and validated low-helium platforms, while making it harder for niche players to compete on price alone. If AI reconstruction materially reduces repeat scans, the immediate loser is not just a rival OEM but also any adjacent imaging workflow vendor whose value proposition depends on manual post-processing.

Near term, this is mostly a sentiment-positive but low-conviction setup; the true catalyst is upcoming order/backlog commentary and hospital capex budgets over the next 1-3 quarters. The contrarian risk is that replacement demand gets pushed out by constrained hospital budgets and reimbursement pressure, so the market may be overestimating the speed of premium upgrades. What would falsify the bullish read: a deceleration in MRI orders, weaker service growth, or management commentary that low-helium/AI attach rates are not improving ASPs.

Key Decisions for Investors

• Prefer GEHC over PHG on a 3-6 month horizon: long GEHC / short PHG as a quality-execution pair, betting that service density and workflow attach outperform hardware-only share gains; target 8-12% relative outperformance if MRI mix improves.
• Watch SMMNY as the cleaner structural beneficiary of premium replacement cycles; add on any post-earnings weakness only if order growth and service backlog remain intact.
• Avoid chasing the article as a broad healthcare-long signal; instead treat it as a rotation within med-tech toward OEMs with recurring service and software revenue, not imaging component suppliers.
• Set a catalyst alert for next quarterly OEM commentary: if MRI order growth or installed-base service growth disappoints, fade the move and reduce exposure immediately.